论文部分内容阅读
目的观察舒洛地特对糖尿病肾病(DN)的疗效。方法将76例DN-Ⅳ期患者随机分为两组:舒洛地特与合厄贝沙坦联合组38例,单用厄贝沙坦组38例,随访12周。比较治疗前后24 h尿蛋白定量、BUN、血肌酐、血清光抑素C(Cys-C)的变化。结果治疗后两组24h尿蛋白均较治疗前有显著下降(P<0.05),联合组与厄贝沙坦组比较差异有统计学意义(P<0.05)。结论舒洛地特联合厄贝沙坦能有效降低DN患者的尿蛋白,效果优于单用厄贝沙坦。
Objective To observe the effect of sulodentid on diabetic nephropathy (DN). Methods Seventy-six patients with DN-Ⅳ were randomly divided into two groups: 38 patients in combination with irbesartan and 38 patients in irbesartan alone. The patients were followed up for 12 weeks. The changes of urinary protein, BUN, serum creatinine and serum Cys-C in 24 hours before and after treatment were compared. Results After treatment, the urinary protein levels of 24 hours were significantly lower than those before treatment (P <0.05). There was significant difference between the combination group and irbesartan group (P <0.05). Conclusions Both sulodexide and irbesartan can effectively reduce urinary protein in patients with DN, which is superior to irbesartan alone.